Monitoring and Baseline Assessment for Intravenous Methylprednisolone in Active Moderate‑to‑Severe Thyroid Eye Disease

Baseline Evaluation

• Prior to initiating high‑dose intravenous methylprednisolone, obtain baseline measurements of blood pressure and serum glucose, assess hepatic transaminases, and perform a bone‑density (DEXA) scan when a course of glucocorticoids is expected to last three months or longer. [1][2]

Ongoing Monitoring During Therapy

• Throughout treatment, regularly re‑measure blood pressure and serum glucose, and actively monitor for hyperglycemia, hypertension, and mood alterations. [1][2]

• Conduct periodic evaluations for signs of osteoporosis and avascular necrosis to detect early skeletal complications. [1][2]